Skip to content
Business websites
Business websites
Johnson & Johnson
J&J MedTech
Johnson & Johnson
J&J MedTech
Location
Language
English
Choose your local market.
Global
Global
English
North America
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
India
English
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
About us
Our Credo
Our responsibilities
Sustainability
Access and pricing principles
Social impact
Economic responsibility
Communicable diseases
Our leadership
Our heritage
Our awards
Our innovation
Focus areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Research & development
Our products
Our pipeline
Clinical trials
How we work
Patient engagement
Pre-approval access
Partnerships
Transparency
Careers
Search jobs
Life at J&J
Our teams
Locations
Student opportunities
How we hire
Newsroom
Press releases
Media contacts
Blogs
Menu
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Newsroom
The latest news, information, and stories from Johnson & Johnson Innovative Medicine.
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
252 Results
252 Results
Open
Filters
Sort By
Newest
Newest
Relevance
Oldest
Oncology
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
March 26, 2025
Read more
Immunology
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
March 26, 2025
Read more
Newsroom
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
March 21, 2025
United States
Read more
Immunology
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease
March 20, 2025
United States
Read more
Oncology
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
March 20, 2025
Read more
Immunology
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren’s disease, has now received Fast Track designation
March 18, 2025
Read more
Immunology
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
March 10, 2025
Read more
Immunology
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
March 8, 2025
Read more
Oncology
Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
February 28, 2025
Belgium
Read more
Immunology
TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
February 21, 2025
United States
Read more
1 of 26
Next
Featured stories
Connecting the best of Health&Care
Read more
Johnson & Johnson named a 2023 Fortune World’s Most Admired Company and ranked #1 on the Pharmaceutical Industry list
Read more
The power of precision medicine for patients
April 25, 2024
Gabriele Alegri
Read more
What is a gene mutation?
Read more
